Log in

Forgot password

Not a member?

Register now

Economic study: Cost-effectiveness of SANTYL Ointment with selective debridement* for pressure ulcers (PUs)

  • SANTYL Ointment + selective debridement incurred greater ulcer-free weeks and lower cumulative costs vs selective debridement alone, resulting in an economically dominant incremental cost-effectiveness ratio (ICER) by the end of two years23
  • At the end of two years, 47.0% of wounds in the SANTYL Ointment group and 24.5% of wounds in the control group were epithelialized23
  • Patients treated with SANTYL Ointment experienced a faster time to closure, gaining 17.2 ulcer-free weeks with a concurrent cost savings of $6,445 per patient23

* Selective debridement was defined as sharp debridement using scissors, scalpels, or curettes.

Ulcer-free week was defined as each week the wound is closed in an epithelialized state.

Compared to selective debridement alone, SANTYL Ointment + selective debridement resulted in:

$375

savings

per ulcer-free week†23


17.2

more weeks

ulcer-free23

The addition of SANTYL Ointment to selective debridement resulted in a concurrent cost savings of $6,445 per patient at two years23
Study details

Study overview, endpoints, and design

Carter MJ, et al. (2017)23
Objective Determine the cost-effectiveness of adding SANTYL Ointment to selective debridement compared with selective debridement alone in the treatment of stage IV PUs among patients in a hospital outpatient department setting.
Primary endpoint
  • Clinical outcome (ulcer-free weeks)
  • ICER (cost per ulcer-free week) at two years
  • Cumulative costs (in US dollars)
Patient demographics Two matched groups of patients with stage IV PUs:
  • SANTYL Ointment + selective debridement group (n=202)
  • Selective debridement group (n=232)

Groups matched for gender (~50% male), race (~63% Caucasian), and ambulatory (~64%)

Design

Markov simulation over a two-year horizon based on real-world outcomes data and resource utilization from the USWR

  • Three health states in the model: non-epithelialized, epithelialized, and death
  • Four-week cycles were used to examine the costs and outcomes associated with the three Markov health states
Limitations
  • Relatively small samples used
  • Epithelialization rates simplified
  • Model did not incorporate ulcer recurrence and severe complications
  • Other adjunctive therapies not considered
  • Mortality rates modeled on national census statistics
  • Results may not be relevant to PUs in other locations, or treatment in outpatient or long-term care setting
Study results

Pressure ulcers treated with SANTYL Ointment resulted in higher cumulative cost savings over two years

  • SANTYL Ointment + selective debridement incurred greater ulcer-free weeks and lower cumulative costs vs selective debridement alone, resulting in an economically dominant ICER by the end of two years23
  • At the end of two years, 47.0% of wounds in the SANTYL Ointment group and 24.5% of wounds in the control group were epithelialized23
  • Patients treated with SANTYL Ointment experienced a faster time to closure, gaining 17.2 ulcer-free weeks with a concurrent cost savings of $6,445 per patient23

Log in or register to download clinical study: Economic study: Cost-effectiveness of SANTYL Ointment with selective debridement for pressure ulcers

What's next?

Hospital inpatient/outpatient re-encounters with SANTYL Ointment vs medicinal honey

Important Safety Information:Use of SANTYL Ointment should be terminated when debridement is complete and granulation tissue is well established.

One case of systemic hypersensitivity has been reported after 1 year of treatment with collagenase and cortisone. Occasional slight transient erythema has been noted in surrounding tissue when applied outside the wound.